Pila Pharma AB (publ) (STO:PILA)
Sweden · Delayed Price · Currency is SEK 1.470
-0.030 (-2.00%)
Sep 4, 2026, 11:58 AM CET
Pila Pharma AB Revenue
Pila Pharma AB had revenue of 275.74K SEK in the twelve months ending June 30, 2026, down -71.21% year-over-year. In the year 2025, Pila Pharma AB had annual revenue of 1.13M with 42.65% growth.
Revenue (ttm)
275.74K
Revenue Growth
-71.21%
P/S Ratio
248.51
Revenue / Employee
275.74K
Employees
1
Market Cap
68.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.13M | 336.85K | 42.65% |
| Dec 31, 2024 | 789.89K | -673.13K | -46.01% |
| Dec 31, 2023 | 1.46M | -417.72K | -22.21% |
| Dec 31, 2022 | 1.88M | 1.16M | 161.49% |
| Dec 31, 2021 | 719.23K | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 346.44K | 320.76K | 1,249.10% |
| Dec 31, 2018 | 25.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 136.17M |
| ExpreS2ion Biotech Holding AB | 24.25M |
| Fluicell AB | 22.19M |
| Biovica International AB | 13.49M |
| NextCell Pharma AB | 10.78M |
| AcouSort AB | 9.31M |
| OncoZenge AB | 5.97M |
| Spago Nanomedical AB | 3.81M |
Pila Pharma AB News
- 8 days ago - Pila Pharma AB Quarterly report: H1 2026 - Filings
- 6 months ago - Pila Pharma AB Quarterly report: H2 2025 - Filings
- 6 months ago - Pila Pharma AB Annual report: H2 2025 - Filings